Table 2 IPD-only and IPD and aggregate network results for mean change in BCVA (ETDRS letters)

Comparison

Covariable adjustment

Model

Mean difference

95% Crl

Mean difference

95% Crl

IVT-AFL 2q8 vs laser

None

Fixed

+ 10.32^a

8.31–12.34

+ 10.32^a

8.30–12.35

Random

+ 10.47^a

6.92–14.16

+ 10.45^a

7.81–13.12

Common (baseline BCVA)

Fixed

+ 10.30^a

8.82–11.78

+ 10.27^a

8.79–11.74

Random

+ 10.54^a

7.07–14.42

+ 10.47^a

7.88–13.11

Treatment-specific

Fixed

+ 10.48^a

8.99–11.97

–

–

Random

+ 10.65^a

7.13–14.34

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN

None

Fixed

+ 3.92^a

0.60–7.24

+ 4.42^a

2.07–6.76

Random

+ 3.47

−3.14–10.44

+ 5.15^a

1.82–8.54

Common (baseline BCVA)

Fixed

+ 3.14^a

0.48–5.80

+ 4.95^a

3.09–6.83

Random

+ 3.54

−2.93–10.81

+ 5.20^a

1.90–8.52

Treatment-specific

Fixed

+ 3.09^a

0.44–5.72

–

–

Random

+ 3.38

−3.20–10.18

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser

None

Fixed

+ 5.96^a

2.65–9.25

+ 5.17^a

2.73–7.61

Random

+ 6.05^a

0.45–12.19

+ 5.95^a

2.60–9.37

Common (baseline BCVA)

Fixed

+ 5.71^a

3.11–8.29

+ 5.77^a

3.81–7.74

Random

+ 6.16^a

0.67–12.55

+ 6.00^a

2.66–9.36

Treatment-specific

Fixed

+ 5.68^a

3.06–8.29

–

–

Random

+ 6.03^a

0.51–11.94

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E

None

Fixed

–

–

+ 5.06^a

1.88–8.23

Random

+ 5.07

−0.37–10.54

Common (baseline BCVA)

Fixed

–

–

+ 4.90^a

2.06–7.72

Random

+ 5.15

−0.26–10.61

Treatment-specific

Fixed

–

–

–

–

Random

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser

None

Fixed

–

–

+ 5.07^a

2.00–8.13

Random

+ 3.80

− 1.57–9.25

Common (baseline BCVA)

Fixed

–

–

+ 3.65^a

0.94–6.35

Random

+ 3.90

−1.42–9.25

Treatment-specific

Fixed

–

–

–

–

Random